Market Overview:
The global IBD (Ulcerative Colitis and Crohn's Disease) treatment market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of IBD, rising awareness about IBD, and technological advancements in the field of IBD treatment. The global IBD (Ulcerative Colitis and Crohn's Disease) treatment market is segmented on the basis of type, application, and region. On the basis of type, the market is segmented into TNF inhibitors, aminosalicylates, integrin antagonists, corticosteroids. On the basis of application,the market is segmented into hospital pharmacies,, retail pharmacies,, online pharmacies,.On th ebasis o fregion ,t hema rketisp egte ntedint ohorizontal segments namely North America,, Latin America,, Europe,,,, Asia Pacific,,,, Middle East & Africa . Some o fth ema jorplayers i nt hismarket are AbbVie Inc., Amgen Inc., AstraZeneca plc., Bristol-Myers Squibb Company Bayer AG Johnson & Johnson Merck & Co., Pfizer Inc., Roche Holding AG Sanofi S.
 Treatment Industry Outlook.svg)
Product Definition:
Inflammatory bowel disease (IBD) is a general term that refers to two specific diseases: ulcerative colitis and Crohn's disease. IBD is a chronic condition that causes inflammation in the digestive tract. This can lead to pain, diarrhea, and other symptoms. IBD can also increase the risk of other health problems, such as cancer. Treatment for IBD depends on the individual's symptoms and what is causing the inflammation.
TNF Inhibitors:
TNF inhibitors, it's usage and growth factor in IBD (Ulcerative Colitis and Crohn's Disease) treatment market size was valued at USD 4.1 billion in 2015. The global TNF inhibitors, it's usage and growth factor in IBD (Ulcerative Colitis and Crohn's Disease) treatment market is expected to witness significant growth over the forecast period owing to the increasing prevalence of Inflammatory Bowel Diseases (IBD).
Aminosalicylates:
Aminosalicylates is a group of drugs that works by reducing the inflammation caused by ulcerative colitis and Crohn's disease. The drug class also includes other medications such as aminosalicylates, mesalicylates, and fosfomycin.
Application Insights:
The retail pharmacies segment held the largest share of 60.0% in 2017 owing to the availability of a large number of treatment options and increasing awareness among patients regarding their disease condition. Moreover, growing penetration of online pharmacies is expected to create opportunities for market growth during the forecast period as these online pharmacies provide convenience and flexibility along with transparency in medication management.
Global IBD (Ulcerative Colitis.
The hospital pharmacy segment is anticipated to register significant growth over the forecast period due to rising prevalence rates coupled with an increase in healthcare expenditure globally. For instance, according to WHO data published in 2019, global healthcare expenditure increased by USD 870 billion from 2013 till 2018 globally which was witnessed an increase from USD 956 billion spent on healthcare during 2008-2013 period worldwide.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of key pharmaceutical companies, such as Pfizer Inc., and Crohn's & Colitis Foundation, in this region. Moreover, increasing prevalence of ulcerative colitis and Crohn's disease is also one of the major factors responsible for its largest share. According to an article published by NCBI, in 2018 around 1 million Americans were diagnosed with IBD out of which Ulcerative Colitis accounted for 0.7% and Crohn’s Disease accounted for 0.9%.
Asia Pacific is expected to witness lucrative growth over the forecast period owing to high unmet clinical needs coupled with growing healthcare expenditure levels especially in developing countries like India & China & Japan etc.;).
Growth Factors:
- Increasing incidence of IBD across the globe
- Growing awareness about the disease among people
- Rising demand for better and effective treatment options for IBD patients
- Technological advancements in diagnosis and treatment of IBD
- Availability of government funding and support for research on IBD
Scope Of The Report
Report Attributes
Report Details
Report Title
IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Research Report
By Type
TNF Inhibitors, Aminosalicylates, Integrin Antagonists, Corticosteroids
By Application
Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
By Companies
AbbVie, Pfizer, Janssen Biotech?Inc.(Johnson?Johnson), Allergan, Bausch Health Companies, Takeda Pharmaceutical Company, Novartis, Biogen
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
249
Number of Tables & Figures
175
Customization Available
Yes, the report can be customized as per your need.
Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Report Segments:
The global IBD (Ulcerative Colitis and Crohn's Disease) Treatment market is segmented on the basis of:
Types
TNF Inhibitors, Aminosalicylates, Integrin Antagonists, Corticosteroids
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- AbbVie
- Pfizer
- Janssen Biotech?Inc.(Johnson?Johnson)
- Allergan
- Bausch Health Companies
- Takeda Pharmaceutical Company
- Novartis
- Biogen
 Treatment Market Overview.svg)
Highlights of The IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- TNF Inhibitors
- Aminosalicylates
- Integrin Antagonists
- Corticosteroids
- By Application:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
 Treatment Market Statistics.svg)
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
IBD treatment typically includes medications, lifestyle changes, and surgery. Medications may include steroids, immunosuppressants (such as azathioprine or 6-mercaptopurine), and anti-inflammatory drugs (such as ibuprofen). Lifestyle changes may include a healthy diet and regular exercise. Surgery may be needed to remove the affected part of the intestine (ileum) or to replace it with a new one.
Some of the major companies in the ibd (ulcerative colitis and crohn's disease) treatment market are AbbVie, Pfizer, Janssen Biotech?Inc.(Johnson?Johnson), Allergan, Bausch Health Companies, Takeda Pharmaceutical Company, Novartis, Biogen.
The ibd (ulcerative colitis and crohn's disease) treatment market is expected to register a CAGR of 7.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market - Supply Chain
4.5. Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Forecast
4.5.1. IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Size (000 Units) and Y-o-Y Growth
4.5.3. IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Absolute $ Opportunity
5. Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Size and Volume Forecast by Type
5.3.1. TNF Inhibitors
5.3.2. Aminosalicylates
5.3.3. Integrin Antagonists
5.3.4. Corticosteroids
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Size and Volume Forecast by Application
6.3.1. Hospital Pharmacies
6.3.2. Retail Pharmacies
6.3.3. Online Pharmacies
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Demand Share Forecast, 2019-2026
9. North America IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Size and Volume Forecast by Application
9.4.1. Hospital Pharmacies
9.4.2. Retail Pharmacies
9.4.3. Online Pharmacies
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Size and Volume Forecast by Type
9.7.1. TNF Inhibitors
9.7.2. Aminosalicylates
9.7.3. Integrin Antagonists
9.7.4. Corticosteroids
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America IBD (Ulcerative Colitis and Crohn's Disease) Treatment Demand Share Forecast, 2019-2026
10. Latin America IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Size and Volume Forecast by Application
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies
10.4.3. Online Pharmacies
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Size and Volume Forecast by Type
10.7.1. TNF Inhibitors
10.7.2. Aminosalicylates
10.7.3. Integrin Antagonists
10.7.4. Corticosteroids
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America IBD (Ulcerative Colitis and Crohn's Disease) Treatment Demand Share Forecast, 2019-2026
11. Europe IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Size and Volume Forecast by Application
11.4.1. Hospital Pharmacies
11.4.2. Retail Pharmacies
11.4.3. Online Pharmacies
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Appliction
11.7. Europe IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Size and Volume Forecast by Type
11.7.1. TNF Inhibitors
11.7.2. Aminosalicylates
11.7.3. Integrin Antagonists
11.7.4. Corticosteroids
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe IBD (Ulcerative Colitis and Crohn's Disease) Treatment Demand Share, 2019-2026
12. Asia Pacific IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Size and Volume Forecast by Application
12.4.1. Hospital Pharmacies
12.4.2. Retail Pharmacies
12.4.3. Online Pharmacies
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Size and Volume Forecast by Type
12.7.1. TNF Inhibitors
12.7.2. Aminosalicylates
12.7.3. Integrin Antagonists
12.7.4. Corticosteroids
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific IBD (Ulcerative Colitis and Crohn's Disease) Treatment Demand Share, 2019-2026
13. Middle East & Africa IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Size and Volume Forecast by Application
13.4.1. Hospital Pharmacies
13.4.2. Retail Pharmacies
13.4.3. Online Pharmacies
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Size and Volume Forecast by Type
13.7.1. TNF Inhibitors
13.7.2. Aminosalicylates
13.7.3. Integrin Antagonists
13.7.4. Corticosteroids
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa IBD (Ulcerative Colitis and Crohn's Disease) Treatment Demand Share, 2019-2026
14. Competition Landscape
14.1. Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market: Market Share Analysis
14.2. IBD (Ulcerative Colitis and Crohn's Disease) Treatment Distributors and Customers
14.3. IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. AbbVie
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Pfizer
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Janssen Biotech?Inc.(Johnson?Johnson)
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Allergan
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Bausch Health Companies
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Takeda Pharmaceutical Company
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Novartis
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Biogen
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
